Herrmann Evan S, Johnson Patrick S, Bruner Natalie R, Vandrey Ryan, Johnson Matthew W
Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States.
Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States.
Drug Alcohol Depend. 2017 Sep 1;178:291-295. doi: 10.1016/j.drugalcdep.2017.05.013. Epub 2017 Jun 20.
Use of amphetamine-type stimulants (e.g., methamphetamine) is associated with acute sleep disruptions. No prior reports have characterized the acute effects of methamphetamine on sleep using polysomnography, the gold standard for objective sleep monitoring.
Recreational stimulant users (n=19) completed a baseline assessment, which included questionnaires assessing demographic and substance use characteristics, and the Pittsburgh Sleep Quality Index (PSQI), which assesses sleep quality over the past month. Participants were administered 0mg (placebo), 20mg, or 40mg oral methamphetamine at 08:15h on study days, using a double-blind, randomized, within-subjects design. Sleep was monitored using polysomnography from 22:20 that evening until 06:15 the following morning.
PSQI scores indicated more than half of participants reported poor sleep quality at baseline. Methamphetamine dose-dependently increased sleep latency, and decreased total sleep time, sleep efficiency, time in NREM 2 sleep, number of REM periods, and total time in REM sleep. Sleep under placebo conditions was consistent with what would be expected from healthy adults.
Morning oral administration of methamphetamine produces robust disruptions in nighttime sleep. Future research should examine relations between stimulant use and sleep disruption in naturalistic settings, with regard to both stimulant abuse and licit prescription use.
使用苯丙胺类兴奋剂(如甲基苯丙胺)与急性睡眠中断有关。此前尚无报告使用多导睡眠图(客观睡眠监测的金标准)来描述甲基苯丙胺对睡眠的急性影响。
娱乐性兴奋剂使用者(n = 19)完成了一项基线评估,包括评估人口统计学和物质使用特征的问卷,以及评估过去一个月睡眠质量的匹兹堡睡眠质量指数(PSQI)。在研究日的08:15,采用双盲、随机、受试者内设计,让参与者口服0mg(安慰剂)、20mg或40mg甲基苯丙胺。从当晚22:20至次日上午06:15使用多导睡眠图监测睡眠情况。
PSQI评分表明,超过一半的参与者在基线时报告睡眠质量较差。甲基苯丙胺剂量依赖性地增加睡眠潜伏期,减少总睡眠时间、睡眠效率、NREM 2睡眠时长、快速眼动(REM)周期数以及REM睡眠总时长。安慰剂条件下的睡眠情况与健康成年人预期的情况一致。
早晨口服甲基苯丙胺会对夜间睡眠产生严重干扰。未来的研究应考察在自然环境中,兴奋剂使用(包括兴奋剂滥用和合法处方使用)与睡眠中断之间的关系。